NICE has given a green light for use of MSD’s Keytruda on the NHS to treat some patients with melanoma, with funding to come from the Cancer Drugs Fund.
News
CHMP backs four medicines for approval
Four medicines have taken a giant leap closer to approval having won the backing of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
The PharmaTimes Marketer, Communications Team of the Year & Sales Awards 2018 – winners announced!
The annual PharmaTimes Marketer of the Year and Communications Team of the Year awards ceremonies took place last night at the Tower Hotel London, with a special addition for this year – the PharmaTimes Sales Awards.
BHA, ABPI welcome UK’s EU withdrawal agreement
The Brexit Health Alliance (BHA) has welcomed the agreement on the terms of the UK’s withdrawal from the European Union (EU).
Mission links with AbbVie to develop Alzheimer’s, Parkinson’s therapies
UK drug discovery and development group Mission Therapeutics has signed a deal with AbbVie focusing on early stage development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease.
Shire’s lanadelumab shown to significantly cut HAE attacks
Shire says it presented data showing that its experimental drug lanadelumab provides a significant and clinically meaningful reduction of hereditary angioedema (HAE) attacks.
NICE issues final draft guidelines for Novartis’ Kymriah
NICE has recommended a pioneering cancer treatment for people under the age of 25 with leukaemia in final draft guidelines.
MSD’s Keytruda shows benefit in oesophageal cancer trial
MSD’s Keytruda has shown promise in a late-stage trial testing its safety and efficacy in patients with advanced or metastatic esophageal or esophagogastric junction carcinoma.
Final NICE green light for Pfizer’s Mylotarg
Cost regulators for the NHS in England and Wales have now published final guidelines recommending Mylotarg, alongside daunorubicin and cytarabine, as an option for untreated de novo CD33-positive acute myeloid leukaemia (AML).
NIHR streams £5m into global infectious diseases research
The National Institute for Health Research is streaming £5 million of global health funding into research looking at how infectious diseases spread and develop into epidemics in low- and middle-income countries.
Ipsen’s Cabometyx wins EU nod for liver cancer
Ipsen’s Cabometyx can now be used as monotherapy to treat certain patients with liver cancer following a green light from regulators in Europe.
Lilly files lasmiditan for migraine
Eli Lilly has filed an application in the US to market lasmiditan for the acute treatment of migraine with or without aura in adults.
Entry closes as countdown to the competition & awards ceremony begins
Entry has now closed for the inaugural PharmaTimes Medical & Scientific Awards, join us at the gala dinner awards ceremony where our winners will be revealed.
Priority review for Roche’s Tecentriq/Abraxane combo
US regulators are undertaking a priority review of Roche’s Tecentriq in combination with Abraxane for the treatment of triple-negative breast cancer.
Australian pharma Phebra sets up UK operations
Australian pharma Phebra has set up operations in the UK with the establishment of a new wholly-owned subsidiary company.
